

# Survey: U.S. Biotechs Sound the Alarm

## *Trade War Threatens Patients and Innovation<sup>1</sup>*

Tariffs will upend the supply chains of American biotech companies – driving up costs, stifling medical progress, and restricting access to life-saving treatments.

**89% of American biotechs rely on imported materials for at least half of their FDA-approved products.**



### Tariffs Threaten Access to Affordable Medicines

- Tariffs on **European Union and Canadian imports** would increase manufacturing costs for **94% and 82%** of biotech firms, respectively.
- **70% of companies** anticipate higher manufacturing costs due to tariffs on China.



### Tariffs Will Stall Medical Innovation

- Tariffs on the **European Union** would force **50% of biotech firms** to identify new research and manufacturing partners.
- Half of companies anticipate having to **rework regulatory filings**, delaying life-saving drugs from reaching patients.
- The uncertainty of tariffs threatens **vital research projects**, putting **American biomedical leadership** at risk.
- **More than 50% of biotech firms** predict “increased difficulty” in **funding and conducting research** if EU tariffs are enacted.



### Tariffs Create Red Tape and Immediate Harm

- Sudden tariffs **punish American companies** – and the **workers and patients** who rely on them.
- **80% of biotech firms** would need **at least 12 months** to find alternative suppliers; **44% would need over two years**.
- The United States does not currently have enough domestic manufacturing capacity to meet demand.
- **To protect patients, medicines have historically been exempt from tariffs.**



### Protect American Biotech. Protect American Patients.

To secure the U.S. supply chain and ensure America remains the global leader in medical innovation, we must:

- **Expedite regulatory pathways** to accelerate the approval of life-saving treatments.
- **Strengthen capital formation** to fuel the next generation of biotech breakthroughs.
- **Protect and advance strong intellectual property rights**, the foundation of America's innovation.

1. Survey of U.S. biotech companies conducted in February 2025. Companies surveyed ranged from emerging (pre-revenue, fewer than 10 employees) to large cap (revenue > \$1 billion).